Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Diffuse large B-cell lymphoma in a patient with dermatomyositis-associated interstitial lung disease: A case report.

Li S, Sun Y, Shao C, Xu K, Huang H.

Thorac Cancer. 2019 Oct;10(10):2035-2039. doi: 10.1111/1759-7714.13171. Epub 2019 Aug 26.

2.

Multiple values of 18F-FDG PET/CT in idiopathic inflammatory myopathy.

Li Y, Zhou Y, Wang Q.

Clin Rheumatol. 2017 Oct;36(10):2297-2305. doi: 10.1007/s10067-017-3794-3. Epub 2017 Aug 22.

PMID:
28831580
3.

Clinical value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis.

Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, Higuchi T, Hirasawa H, Kodaira S, Tomonaga H, Tsushima Y, Ishikawa O.

J Dermatol. 2019 Mar;46(3):213-218. doi: 10.1111/1346-8138.14758. Epub 2019 Jan 4.

PMID:
30614031
4.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
5.

A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.

Kim KM, Yoon DH, Lee SG, Lim SN, Sug LJ, Huh J, Suh C.

J Korean Med Sci. 2009 Jun;24(3):525-8. doi: 10.3346/jkms.2009.24.3.525. Epub 2009 Jun 16.

6.

Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Koyama RVL, Braga TKK, da Silva Dias GA, Fujihara S, Fuzii HT, Yoshikawa GT.

Clin Rheumatol. 2017 Aug;36(8):1919-1926. doi: 10.1007/s10067-017-3671-0. Epub 2017 May 9. Review.

PMID:
28488124
7.
8.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
9.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.

Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.

10.

Rituximab-induced interstitial lung disease.

Wagner SA, Mehta AC, Laber DA.

Am J Hematol. 2007 Oct;82(10):916-9. Review.

11.

Differentiation of sarcoidosis-lymphoma syndrome lesions: a case report on the use of two different positron emission tomography tracers.

Yudistiro R, Arisaka Y, Tokue A, Nakajima T.

BMC Med Imaging. 2016 Jan 8;16:1. doi: 10.1186/s12880-015-0104-x.

12.

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.

Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19.

14.

Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.

Yamada K, Asai K, Okamoto A, Watanabe T, Kanazawa H, Ohata M, Ohsawa M, Hirata K.

BMC Res Notes. 2018 Jan 16;11(1):34. doi: 10.1186/s13104-018-3146-7.

15.

[Interstitial pneumonitis as a side effect of rituximab].

Kemming JL, van Zeeland RE, Ullmann EF, Mattijssen EJ.

Ned Tijdschr Geneeskd. 2009;153:A526. Dutch.

PMID:
19785875
16.

[Successful treatment with preceding low-intensity chemotherapy in a primary mediastinal large B cell lymphoma patient diagnosed at 11 weeks of pregnancy].

Hattori D, Yahagi Y, Uryu H, Hosoba R, Momoki M, Nagao R, Yamazaki H.

Rinsho Ketsueki. 2019;60(2):112-117. doi: 10.11406/rinketsu.60.112. Japanese.

PMID:
30842377
17.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
18.

Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report.

Aagre S, Patel A, Kendre P, Anand A.

Lung India. 2015 Nov-Dec;32(6):620-3. doi: 10.4103/0970-2113.168135.

19.

Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology.

Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE.

Arthritis Rheum. 2008 May 15;59(5):677-85. doi: 10.1002/art.23571.

20.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386

Supplemental Content

Support Center